Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
NCT00002679
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating patients with stage II or stage III breast cancer who have four or more positive axillary lymph nodes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2009
Locations: Yale Comprehensive Cancer Center, New Haven, Connecticut
Conditions: Breast Cancer
Register for Updates
Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
NCT00296205
Withdrawn
The purpose of this study is to determine what percentage of patients receiving high-dose Cyclophosphamide may experience a halt in the worsening of their disease or experience improvement of their disease and for how long the benefit may last.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/21/2009
Locations: Stony Brook University Hospital, Stony Brook, New York
Conditions: Multiple Sclerosis
Register for Updates
Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease
NCT00186810
Completed
This protocol studied the effect of administration of a myeloablative pretransplant preparative regimen followed by an infusion of donor stem cells in children with severe sickle cell disease. The donor graft consisted of bone marrow or cord blood derived from a genetically matched sibling. The primary aim of the study was to evaluate how well the donated cells migrated to the bone marrow and begin producing healthy red blood cells, white blood cells and platelets (engrafted), how well the reci... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/28/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates
Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00186849
Completed
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/19/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00070083
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of a chemotherapy drug by making cancer cells more sensitive to the drug. Combining oblimersen with rituxi... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/04/2009
Locations: Stanford Cancer Center at Stanford University Medical Center, Stanford, California +3 locations
Conditions: Lymphoma
Register for Updates
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT00438841
Unknown
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with cyclophosphamide, dexamethasone, and thalidomide may kill more cancer cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2009
Locations: Alta Bates Summit Comprehensive Cancer Center, Berkeley, California +9 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors
NCT00628732
Completed
The purposes of this study include: * Determination of the change in clearance of topotecan and topotecan lactone between day 1 and day 14 for patients receiving treatment with p.o. topotecan and p.o. cyclophosphamide x 14 days. * Determination of the correlation between the activity of CYP3A4, as measured by the 14C- Erythromycin Breath Test (ERMBT), and topotecan/topotecan lactone clearance for patients receiving treatment with p.o. topotecan and p.o. cyclophosphamide x 14 days. * Determinati... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/27/2009
Locations: Children's Medical Center Dallas, Dallas, Texas
Conditions: Solid Tumors
Register for Updates
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
NCT00010413
Completed
OBJECTIVES: I. Determine the response rate and 1-year event-free survival of patients with refractory pemphigus treated with high-dose cyclophosphamide.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/01/2008
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Pemphigus
Register for Updates
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
NCT00578435
Completed
The purpose of this study is to determine and confirm the role of bone marrow transplantation in the treatment of disorders of the red cell and hemoglobin including sickle cell anemia, thalassemia and diamond blackfan anemia.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
09/10/2008
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Genetic Disorders, Sickle Cell Anemia
Register for Updates
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
NCT00010387
Completed
OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
Gender:
ALL
Ages:
All
Trial Updated:
09/08/2008
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland
Conditions: Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
Register for Updates
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
NCT00016458
Completed
OBJECTIVES: I. Determine the toxicity of cyclophosphamide and rabbit anti-thymocyte globulin in patients with diffuse systemic sclerosis. II. Determine the efficacy of this regimen in terms of controlling disease in these patients.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
09/02/2008
Locations: University of Colorado Cancer Center, Denver, Colorado +2 locations
Conditions: Systemic Sclerosis
Register for Updates
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
NCT00705120
Completed
This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III. Compatible sibling donors and unrelated donors were stratified and analyzed according to the type of donor. All patients with a sibling donor will received a chemotherapy conditioning regimen; a non-T cell depleted allogeneic marrow, and GVHD prophylaxis. All patients with an unrelated donor will receive a chemoradiotherapy conditioni... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
06/23/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Osteogenesis Imperfecta
Register for Updates